Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926815 | 0.94 | GPR34 (0.55) | SERPINE1PTPN1GPR34 | |
| SCHEMBL3995385 | 0.93 | GPR132 (0.48) | SERPINE1PTPN1 | |
| SCHEMBL5926197 | 0.93 | SERPINE1 (0.49) | SERPINE1LMNASMN1; SMN2L3MBTL1PTPN1 | |
| SCHEMBL5927527 | 0.93 | SERPINE1 (0.52) | SERPINE1LMNASMN1; SMN2L3MBTL1PTPN1 | |
| SCHEMBL5926619 | 0.91 | ITGA4 (0.47) | SERPINE1LMNAL3MBTL1GPR34ITGB1 | |
| SCHEMBL5927167 | 0.91 | GPR132 (0.51) | SERPINE1PTPN1GPR34 | |
| SCHEMBL5926762 | 0.91 | ITGB1 (0.44) | SERPINE1ITGB1ITGA4ITGB7 | |
| SCHEMBL5926528 | 0.91 | SERPINE1 (0.50) | SERPINE1LMNASMN1; SMN2L3MBTL1PTPN1 | |
| SCHEMBL5926633 | 0.90 | SERPINE1 (0.45) | SERPINE1LMNASMN1; SMN2L3MBTL1PTPN1 | |
| SCHEMBL5927230 | 0.90 | GRN (0.47) | SERPINE1LMNASMN1; SMN2L3MBTL1GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | SERPINE1 27/4885LMNA 178/4885SMN1; SMN2 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.